Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18

Vaccine

Volumn 24, Issue 27-28, 2006, Pages 5571-5583

  Villa, Luisa L ^a   Ault, Kevin A ^b   Giuliano, Anna R ^c   Costa, Ronaldo L R ^d   Petta, Carlos A ^e   Andrade, Rosires P ^f   Brown, Darron R ^g   Ferenczy, Alex ^h   Harper, Diane M ⁱ   Koutsky, Laura A ^j   Kurman, Robert J ^k   Lehtinen, Matti ^l   Malm, Christian ^l   Olsson, Sven Eric ^m   Ronnett, Brigitte M ^k   Skjeldestad, Finn Egil ⁿ   Steinwall, Margareta ^o   Stoler, Mark H ^p   Wheeler, Cosette M ^q   Taddeo, Frank J ^r   Yu, Jimmy ^r   Lupinacci, Lisa ^r   Railkar, Radha ^r   Marchese, Rocio ^r   Esser, Mark T ^r   Bryan, Janine ^r   Jansen, Kathrin U ^r   Sings, Heather L ^r   Tamms, Gretchen M ^r   Saah, Alfred J ^r   Barr, Eliav ^r   more..

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Brazil)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d A C CAMARGO CANCER CENTER   (Brazil)

^e UNIVERSITY OF CAMPINAS   (Brazil)

^f CERHFAC Center of Studies and Clinical Research   (Brazil)

^g INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h MCGILL UNIVERSITY   (Canada)

ⁱ DARTMOUTH MEDICAL SCHOOL   (United States)

^j UNIVERSITY OF WASHINGTON   (United States)

^k JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^m DANDERYD HOSPITAL   (Sweden)

ⁿ SINTEF   (Norway)

^o LUND UNIVERSITY HOSPITAL   (Sweden)

^p UNIVERSITY OF VIRGINIA   (United States)

^q UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^r MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

Human papillomavirus; Immunogenicity; Vaccine

Indexed keywords

ANTIBODY; CAPSID PROTEIN; PLACEBO; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; CONDYLOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TARGETING; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; VIRUS PARTICLE;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; FEMALE; HUMAN PAPILLOMAVIRUS 11; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMAN PAPILLOMAVIRUS 6; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; VIRAL VACCINES;

EID: 33746839247     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.04.068     Document Type: Article

References (36)

1. Melbye M., and Frisch M. The role of human papillomaviruses in anogenital cancers. Semin Cancer Biol 8 (1998) 307-313
2. zur Hausen H. Oncogenic DNA viruses. Oncogene 20 (2001) 7820-7823
3. Muñoz N., Bosch F.X., de Sanjosé S., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 6 (2003) 518-527
4. Bosch F.X., Manos M.M., Muñoz N., et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 87 11 (1995) 796-802
5. Maw R.D. Treatment of anogenital warts. Dermatol Clin 16 4 (1998) 829-834
6. Maw R.D., Reitano M., and Roy M. An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle. Int J STD AIDS 9 (1998) 571-578
7. CDC. Genital HPV infection. Genital HPV infection [web site]. Available at: http://www.cdc.gov/std/HPV/STDFact-HPV.html.
8. Ferlay J., Bray F., and Pisani P. Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5, version 2.0 (2004), IARCPress, Lyon
9. Insinga R.P., Glass A.G., and Rush B.B. The health care costs of cervical human papillomavirus-related disease. Am J Obstet Gynecol 191 (2004) 114-120
10. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 102 5A (1997) 3-8
11. Wiley D.J., Douglas J., Beutner K., et al. External genital warts: diagnosis, treatment, and prevention. Clin Infect Dis 35 (2002) S210-S224
12. Clifford G.M., Rana R.K., Franceschi S., et al. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 14 (2005) 1157-1164
13. Hofmann K.J., Cook J.C., Joyce J.G., et al. Sequence Determination of Human Papillomavirus Type 6a and Assembly of Virus-like Particles in Saccharomyces cerevisiae. Virology 209 2 (1995) 506-518
14. Emeny R.T., Wheeler C.M., Jansen K.U., et al. Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine. J Virol 76 15 (2002) 7832-7842
15. Brown D.R., Fife K.H., Wheeler C.M., et al. Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. Vaccine 22 (2004) 2936-2942
16. Fife K.H., Wheeler C.M., Koutsky L.A., et al. Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women. Vaccine 22 (2004) 2943-2952
17. Ault K., Giuliano A.R., Edwards R., et al. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. Vaccine 22 23-24 (2004) 3004-3007
18. Brown D.R., Bryan J.T., Schroeder J.M., et al. Neutralization of human papillomarvirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer. J. Infect Dis 184 (2001) 1183-1186
19. Harper D.M., Franco E.L., Wheeler C.M., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection of human papillomavirus type 16 and 18 in young women: a randomised controlled trial. Lancet 364 9447 (2004) 1757-1765
20. Villa L.L., Costa R.L.R., Petta C.A., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 5 (2005) 271-278
21. Poland G.A., Gregory A., Jacobson R.M., et al. Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial. Mayo Clinic Proc 80 5 (2005) 601-610
22. Koutsky L.A., Ault K.A., Wheeler C.M., et al. A Controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347 21 (2002) 1645-1651
23. Opalka D., Lachman C.E., MacMullen S.A., et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 10 1 (2003) 108-115
24. Palker T.J., Monteiro J.M., and Martin M.M. Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles. Vaccine 19 (2001) 3733-3743
25. ® Assay to Quantify Antibodies to Neutralizing Epitopes on Human Papillomavirus 6, 11, 16 & 18. Clin Diagn Lab Immunol 12 8 (2005) 959-969
26. Christensen N.D., Reed C.A., Cladel N.M., Hall K., and Leiserowitz S. Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6. Virology 224 (1996) 477-486
27. Christensen N.D. Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6. Virology 64 11 (1990) 5678-5681
28. Christensen N.D., Dillner J., Eklund C., et al. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 223 (1996) 174-184
29. O'Connell M., Belanger B., and Haaland P. The four parameter logistic model for calibration and assay development. Am Stat Assoc Proc Biopharm Sec (1992) 180-185
30. Miettinen O., and Nurminen M. Comparative analysis of two rates. Stat Med 4 (1985) 213-226
31. McMahon B., Bruden D., Petersen K., et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med 142 5 (2005) 333-341
32. Whittle H., Jaffar S., Wansbrough M., et al. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ 325 (2002) 569-570
33. Viviani S., Jack A., Hall A.J., et al. Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. Vaccine 17 23-24 (1999) 2946-2950
34. Molano M., Posso H., Weiderpass E., et al. Prevalence and determinants of HPV infection among colombian women with normal cytology. Br J Cancer 87 (2002) 324-333
35. Peto J., Gilham C., Deacon J., et al. Cervical HPV infectionand neoplasia in a large population-basedprospective study: the Manchester cohort. Br J Cancer 91 (2004) 942-953
36. Ruiz W., McClements W.L., Jansen K.U., and Esser M.T. Kinetics and isotype profile of antibody responses in rhesus macaques induced following vaccination with HPV 6, 11, 16, and 18 L1-virus-like particles formulated with or without Merck aluminum adjuvant. Journal of Immune Based Therapies and Vaccines 3 1 (2005) 2